|
|
Volumn 9, Issue 12, 2010, Pages 908-
|
|
Trial watch: Success for crizotinib in ALK-driven cancer
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE;
ANAPLASTIC LYMPHOMA KINASE;
BCR ABL PROTEIN;
CRIZOTINIB;
GEFITINIB;
IMATINIB;
NUCLEOPHOSMIN;
UNCLASSIFIED DRUG;
CLINICAL TRIAL;
DRUG EFFICACY;
DRUG RESPONSE;
DRUG TOLERABILITY;
ENZYME INHIBITION;
GASTROINTESTINAL SYMPTOM;
GENE REARRANGEMENT;
GENE TRANSLOCATION;
HUMAN;
LARGE CELL LYMPHOMA;
LUNG CARCINOGENESIS;
LUNG NON SMALL CELL CANCER;
MALIGNANT NEOPLASTIC DISEASE;
NEUROBLASTOMA;
PLASMA CELL GRANULOMA;
POINT MUTATION;
PRIORITY JOURNAL;
SHORT SURVEY;
TUMOR GROWTH;
ANTINEOPLASTIC AGENTS;
CARCINOMA, NON-SMALL-CELL LUNG;
CLINICAL TRIALS, PHASE I AS TOPIC;
HUMANS;
LYMPHOMA, LARGE-CELL, ANAPLASTIC;
NEOPLASMS;
PROTEIN KINASE INHIBITORS;
PROTEIN-TYROSINE KINASES;
PYRAZOLES;
PYRIDINES;
|
|
EID: 78649716061
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3328 Document Type: Short Survey |
|
Times cited : (5)
|
|
References (0)
|